Assessment and Treatment of Anxiety Disorders in Children and Adolescents
- 5.6k Downloads
Recent advances in the developmental epidemiology, neurobiology, and treatment of pediatric anxiety disorders have increased our understanding of these conditions and herald improved outcomes for affected children and adolescents. This article reviews the current epidemiology, longitudinal trajectory, and neurobiology of anxiety disorders in youth. Additionally, we summarize the current evidence for both psychotherapeutic and psychopharmacologic treatments of fear-based anxiety disorders (e.g., generalized, social, and separation anxiety disorders) in children and adolescents. Current data suggest that these disorders begin in childhood and adolescence, exhibit homotypic continuity, and increase the risk of secondary anxiety and mood disorders. Psychopharmacologic trials involving selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SSNRIs) are effective in pediatric patients with anxiety disorders and have generally demonstrated moderate effect sizes. Additionally, current data support cognitive behavioral therapy (CBT) for the treatment of these conditions in youth and suggest that the combination of psychotherapy + an SSRI may be associated with greater improvement than would be expected with either treatment as monotherapy.
KeywordsAntidepressant Anxiety disorders
Selective serotonin reuptake inhibitor
Separation anxiety disorder
Generalized anxiety disorder
Compliance with Ethics Guidelines
Conflict of Interest
Katja Beesdo-Baum and Meghann M. Hennelly declare that they have no conflict of interest.
Anna M. Wehry has received a grant from the American Academy of Child and Adolescent Psychiatry.
Sucheta D. Connolly has received a grant from the National Institute of Mental Health, 1R01MH086517, (01 Jul. 2010–31 Mar. 2015) (Phan and Monk, co-PIs) Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents. Role: coinvestigator.
Jeffrey R. Strawn has received research support from Edgemont, Eli Lilly, Shire, Forest Research Institute and the National Institute of Mental Health (NIMH).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Merikangas KR, He JP, Burnstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–9.PubMedCentralPubMedCrossRefGoogle Scholar
- 5.Beesdo-Baum K, Pine DS, Lieb R, Wittchen J. Mental disorders in adolescence and young adulthood: homotypic and heterotypic longitudinal associations. American College of Neuropsychopharmacology 51st Annual Meeting, Hollywood, Florida, 2012.Google Scholar
- 19.Wittchen H-U, Lieb R, Pfister H, Schuster P. The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. Compr Psychiatry. 2000;41: 2, Suppl 1:122-132.Google Scholar
- 40.•Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, et al. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014;53:297–310. This analyses describes long-term outcomes following an acute, double-blind, placebo-controlled trial of sertraline, CBT or sertraline + CBT.PubMedCentralPubMedCrossRefGoogle Scholar
- 66.•Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL. A randomized, placebo-controlled study of duloxetine for the treatment of children (7-11 years) and adolescents (12-17 years) with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(4):283–93. This recent article describes the registration trial for the only USFDA approved antidepressant for GAD in children and adolescents.Google Scholar
- 67.•Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–57. This article represents the only meta-analysis of antidepressants in pediatric patients with non-OCD anxiety disorders and also examines treatment-emergent side effect profiles.PubMedCrossRefGoogle Scholar
- 73.•Compton SN, Peris TS, Almirall D, Birmaher B, Sherrill J, Kendall PC, et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol. 2014;82(2):212–24. A recent analysis of clinical and demographic factors which are associated with differential response to psychopharmacologic and psychotherapeutic response in pediatric patients with anxiety disorders.PubMedCentralPubMedCrossRefGoogle Scholar